SCHEMBL5844082

SCHEMBL5844082

Cc1cc(C)c(N)c(C)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
TDP1 Q9NUW8 2/20 0.43
TP53 P04637 1/20 0.43
CYP3A4 P08684 1/20 0.43
TSHR P16473 1/20 0.43
KDM4E B2RXH2 7/20 0.43
NOS3 P29474 2/20 0.42
NOS1 P29475 2/20 0.42
NOS2 P35228 2/20 0.42
SLC6A2 P23975 1/20 0.42
GRM5 P41594 1/20 0.42
UHRF1 Q96T88 1/20 0.41
IDO1 P14902 1/20 0.41
POLB P06746 5/20 0.39
HPGD P15428 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
LMNA P02545 3/20 0.39
HTT P42858 3/20 0.39
MITF O75030 2/20 0.39
RAD52 P43351 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29512854 1.00 ALDH1A1 (0.43) ALDH1A1TDP1TP53CYP3A4TSHR
SCHEMBL9383607 0.79 NCF1 (0.43) ALDH1A1TDP1KDM4ENOS3NOS1
SCHEMBL5758060 0.79 NOS2 (0.48) ALDH1A1TDP1TP53CYP3A4TSHR
SCHEMBL1279214 0.79 KDM4E (0.54) ALDH1A1TDP1TP53CYP3A4TSHR
SCHEMBL19202623 0.75 CYP3A4 (0.40) ALDH1A1TDP1TP53CYP3A4TSHR
SCHEMBL19203178 0.75 ALDH1A1 (0.40) ALDH1A1TDP1TP53CYP3A4TSHR
SCHEMBL8062164 0.75 NOS3 (0.39) ALDH1A1TDP1CYP3A4KDM4ENOS3
SCHEMBL22030731 0.75 NOS3 (0.39) ALDH1A1TDP1KDM4ENOS3NOS1
SCHEMBL31211070 0.75 NOS3 (0.39) ALDH1A1TSHRKDM4ENOS3NOS1
SCHEMBL3886713 0.75 POLB (0.53) ALDH1A1TDP1TP53CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12613468-B2 Method for forming patterned photoresist TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) 2026-04-28 US claimed
US-20240103375-A1 METHOD FOR FORMING PATTERNED PHOTORESIST TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) 2024-03-28 US claimed
US-11886121-B2 Method for forming patterned photoresist TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) 2024-01-30 US claimed
CN-115449284-B Preparation method of antibacterial mildew-proof leather finishing agent containing plant-source-based efficacy factors 四川大学 2023-05-16 CN claimed
CN-115449284-A Preparation method of antibacterial and mildewproof leather finishing agent containing plant source-based functional factors 四川大学 2022-12-09 CN claimed
US-20210063888-A1 METHOD FOR FORMING PATTERNED PHOTORESIST TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) 2021-03-04 US claimed
WO-2013004617-A1 PYRAZOLOPYRIDINES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM H. LUNDBECK A/S (DK) 2013-01-10 WO claimed
US-20130005743-A1 New positive allosteric modulators of nicotinic acetylcholine receptor H. LUNDBECK A/S (DK) 2013-01-03 US claimed
US-12613468-B2 Method for forming patterned photoresist TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) 2026-04-28 US disclosed
EP-4656602-A2 MEMBRANES FOR REMOVING METALLIC SPECIES FROM AMINES Entegris, Inc. (US) 2025-12-03 EP disclosed
US-20240350984-A1 MEMBRANES FOR REMOVING METALLIC SPECIES FROM AMINES ENTEGRIS, INC. 2024-10-24 US disclosed
US-12059656-B2 Membranes for removing metallic species from amines ENTEGRIS, INC. (US) 2024-08-13 US disclosed
US-20240103375-A1 METHOD FOR FORMING PATTERNED PHOTORESIST TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) 2024-03-28 US disclosed
EP-3532474-B1 4,5-ANNULATED 1,2,4-TRIAZOLONES BAYER AG (DE) 2024-03-27 EP disclosed
WO-1997035539-A2 ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES DU PONT PHARMACEUTICALS COMPANY (US) 1997-10-02 WO disclosed
EP-0784612-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-07-23 EP disclosed
EP-0764166-A1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS PFIZER INC. (US) 1997-03-26 EP disclosed
WO-1996010559-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-04-11 WO disclosed
WO-1995033750-A1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS PFIZER INC. (US) 1995-12-14 WO disclosed
US-RE31244-E Antihypertensive pyridylguanidine compounds LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) 1983-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005743-A1 New positive allosteric modulators of nicotinic acetylcholine receptor CHRNG, CHRNA7, CHRNA1 ALDH1A1 4066/4885TDP1 2407/4885TP53 3711/4885
US-12613468-B2 Method for forming patterned photoresist CD44, PLOD1, ASIC1 ALDH1A1 1113/4885TDP1 4824/4885TP53 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.